Health
Anti-cancer drug’s mode of operation deciphered – EurekAlert
Freiburg researchers show how the membrane protein CD20 keeps the immune system’s antibody-producing cells in check.
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General13 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News22 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General13 hours agoOf saints and sinners | The Spectator Australia